Neoplasms

All Conditions

Digestive System Diseases

Carcinoma

Carcinoma, Hepatocellular

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Amplitude-modulated electromagnetic fields

Boris Pasche, MD, PhD

Hepatocarcinoma (HCC) is the first cause of deaths due to cancer worldwide. More than one million two hundred thousand new patients are diagnosed each year. The prognosis of patients suffering from advanced hepatocarcinoma is poor with an average survival of less than six months. Phase I data suggest that low levels of electromagnetic fields administered intrabucally with a portable and programmable device are a safe and potentially effective treatment for advanced cancer. The device is connected to a spoon-like coupler placed in the patient's mouth during treatment. Patients with advanced HCC and limited therapeutic options will be offered treatment with a combination of frequencies.

Hepatocarcinoma (HCC) is the first cause of deaths due to cancer worldwide. More than one million two hundred thousand new patients are diagnosed each year. The prognosis of patients suffering from advanced hepatocarcinoma is poor with an average survival of less than six months. Therapies for hepatocarcinoma are limited. Resection of the primary tumor is the therapeutic approach of first choice when possible. Although this intervention results in long-term survival for some patients, only a minority of them are surgical candidates because of limitations due to tumor size, patient's overall condition or presence of hepatic cirrhosis.

Phase I data suggest that low levels of amplitude-modulated electromagnetic fields administered intrabucally with a portable and programmable device are a safe and potentially effective treatment for advanced cancer. The device is connected to a spoon-like coupler placed in the patient's mouth during treatment. Patients with advanced HCC and limited therapeutic options will be offered treatment with a combination of HCC-specific frequencies.

The patients will be offered ambulatory treatment, which will be administered three times a day for 60 min until disease progression or death.

A Study of Electromagnetic Waves in the Treatment of the Advanced Hepatocarcinoma

Étude de Phase II Pour déterminer l'efficacité Des Ondes électromagnétiques de Basse intensité administrées Par Voie Buccale Dans le Traitement du Cancer du Foie avancé

Barbault, Alexandre, M.S.

Pasche, Boris, M.D.

Boris Pasche

Nervous System Diseases

Brain Neoplasms

Central Nervous System Neoplasms

Nervous System Neoplasms

Brain Diseases

Central Nervous System Diseases

Low levels of amplitude-modulated electromagnetic fields

Emitter of low levels of amplitude-modulated electromagnetic fields

Boris C Pasche, MD, PhD

In vitro studies suggest that low levels of amplitude-modulated electromagnetic fields may modify cell growth. We have identified specific frequencies that may block cancer cell growth. We have developed a device delivering low levels of amplitude-modulated electromagnetic fields. The device is connected to a spoon-like coupler, which is placed in the patient's mouth during treatment. We will conduct a feasibility study consisting of three daily ambulatory treatments until disease progression.

Background: In vitro studies suggest that low levels of amplitude-modulated electromagnetic fields may modify cell growth. We have identified specific frequencies that may block cancer cell growth. We have developed a portable and programmable device delivering low levels of amplitude-modulated electromagnetic fields. The device is connected to a spoon-like coupler, which is placed in the patient's mouth during treatment.

Methods: We will conducted a feasibility study consisting of three daily treatments. All patients with advanced solid tumors and measurable disease will be eligible, irrespective of prior treatments. Patients will be assessed with laboratory exams (complete blood count, comprehensive profile, tumor markers), imaging studies every other month for the first six months, every third month thereafter.

A Study of Therapeutic Amplitude-modulated Electromagnetic Fields in Advanced Tumors

Treatment of Advanced Cancer With Amplitude-modulated Electromagnetic Fields of Low Intensity by Means of an Intrabuccal Probe

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study of Electromagnetic Waves in the Treatment of the Advanced Hepatocarcinoma	NCT00440934	Carcinoma, Hepa...	Amplitude-modul...	18 Years - 95 Years	Pasche, Boris, M.D.
A Study of Electromagnetic Waves in the Treatment of the Advanced Hepatocarcinoma	NCT00440934	Carcinoma, Hepa...	Amplitude-modul...	18 Years - 95 Years	Pasche, Boris, M.D.
A Study of Therapeutic Amplitude-modulated Electromagnetic Fields in Advanced Tumors	NCT00440570	Cancer Brain Tumor	Low levels of a... Emitter of low ...	18 Years - 95 Years	Pasche, Boris, M.D.
A Study of Therapeutic Amplitude-modulated Electromagnetic Fields in Advanced Tumors	NCT00440570	Cancer Brain Tumor	Low levels of a... Emitter of low ...	18 Years - 95 Years	Pasche, Boris, M.D.

Spots Global Cancer Trial Database for electromagnetic fields